Teva Pharmaceutical Industries Limited (TEVA) Release: Data Demonstrates Key Genes Respond Differently To COPAXONE® (glatiramer acetate injection) Versus A Purported Generic Glatiramer Acetate
1/13/2014 10:49:14 AM
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) today announced the publication of data that demonstrates significant differences in biological and immunological effects between COPAXONE® (glatiramer acetate, GA) and a purported generic glatiramer acetate (GA), marketed in India, (Glatiramer®, Natco Pharma, Ltd., Hyderabad, India), with potential clinical ramifications.
Help employers find you! Check out all the jobs and post your resume.
comments powered by